Mitochondrial complex 1 Inhibitors
1 drugsAbout Mitochondrial complex 1
Mitochondrial complex I, or NADH:ubiquinone oxidoreductase, is a key enzyme in the mitochondrial electron transport chain, initiating cellular respiration and ATP production. As the largest complex, it plays a vital role in cellular energy generation. Disruptions can have far-reaching consequences.
Mitochondrial complex I is a compelling target for drug development, particularly where cellular energy production is compromised. Currently, there is no genetic evidence data available linking mitochondrial complex I to specific diseases.
There is one FDA-approved drug, FLYRCADO (GE HLTHCARE), targeting mitochondrial complex I for cardiovascular conditions. The drug is a small molecule. GE HLTHCARE is the only company with an approved drug.
Top Mitochondrial complex 1 Drugs
GE HLTHCARE is the only company with an approved drug targeting mitochondrial complex I.
Low competition suggests an opportunity for new entrants, but also indicates potential challenges in the target's validation.
Mitochondrial complex 1 Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Mitochondrial complex 1, using small molecule modality.
Explore opportunities for alternative modalities like antibodies or peptides to differentiate from existing therapies.
Mitochondrial complex 1 Clinical Trials 1 trial
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Mitochondrial complex 1. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 2 | 1 | 1 | 0 | 0 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Mitochondrial complex 1 Drug Approval Timeline (2024 - 2024)
The first and most recent drug, FLYRCADO, was approved in 2024.
Recent approval suggests renewed interest, but limited history indicates uncertainty in long-term success.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 1 (0 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Mitochondrial complex 1. A trial counts if an approved drug acting on Mitochondrial complex 1 is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.